According to
GuruFocus Insider Data
, these are the largest CEO buys during the past week. The
overall trend of CEOs is illustrated in the chart below:
CVR Refining LP (
CVRR
): CEO and President John J. Lipinski Bought 200,000
Shares
CEO and President of CVR Refining LP (
CVRR
) John J Lipinski bought 200,000 shares on 01/17/2013 at an
average price of $25 with a P/S ratio of 0.5095.
CFO and Treasurer
Susan M. Ball
bought 8,000 shares of CVRR stock on 01/17/2013 at the average
price of $25. Susan M. Ball owns at least 8,000 shares after
this. Other insiders have also increased their positions in the
company.
Huntington Bancshares Inc (
HBAN
): President, CEO and Chairman Stephen D. Steinour Bought 40,000
Shares
President, CEO and Chairman of Huntington Bancshares Inc (
HBAN
) Stephen D. Steinour bought 40,000 shares on 01/23/2013 at an
average price of $6.93. Huntington Bancshares Inc. was organized
under Maryland law in 1966 and headquartered in Columbus, Ohio.
Huntington Bancshares Inc has a market cap of $5.9 billion; its
shares were traded at around $6.93 with a P/E ratio of 10.5 and
P/S ratio of 2.2. The dividend yield of Huntington Bancshares
Inc. stocks is 2.3%.
Huntington recently reported 2012 full-year net income of $641
million, an increase of $98.4 million, or 18%, from the prior
year. 2012 fourth quarter net income of $167.3 million was
essentially unchanged from the prior quarter. Earnings per common
share for the year and current quarter were $0.71 and $0.19,
respectively, up $0.12 and unchanged from the prior periods.
Ray Dalio
owns 45,031 shares as of 09/30/2012, an increase of 135.38% from
the previous quarter. This position accounts for 0.0042% of the
$7.44 billion portfolio of Bridgewater Associates.
Arnold Schneider
owns 3,699,835 shares as of 09/30/2012, which accounts for 2.3%
of the $1.09 billion portfolio of Schneider Capital Management.
CFO and Sr. Executive Vice President Donald R. Kimble bought
5,000 shares of HBAN stock on 08/15/2012 at the average price of
6.41. Donald R. Kimble owns at least 272,610 shares after this.
The price of the stock has increased by 8.11% since. There are
mixed trades from other insiders.
ValueVision Media Inc. (
VVTV
): CEO Keith R. Stewart Bought 100,000 Shares
CEO of ValueVision Media, Inc. (
VVTV
) Keith R Stewart bought 100,000 shares on 01/18/2013 at an
average price of $2.61. ValueVision Media, Inc. was incorporated
on June 25, 1990. Valuevision Media, Inc. has a market cap of
$127.6 million; its shares were traded at around $2.61 with and
P/S ratio of 0.2.
Executive Vice President and CFO William J. Mcgrath bought 10,000
shares of VVTV stock on 12/03/2012 at the average price of 1.79.
William J. Mcgrath owns at least 106,680 shares after this. The
price of the stock has increased by 45.81% since. Other insiders
have also increased their positions in the company.
SunCoke Energy Partners LP (
SXCP
): Chairman and CEO Frederick A. Henderson Bought 12,000
Shares
Chairman and CEO of SunCoke Energy Partners LP (
SXCP
) Frederick A. Henderson bought 12,000 shares on 01/18/2013 at an
average price of $0. with and P/S ratio of 0.8687.
SunCoke recently reported its fourth quarter preliminary results.
Total U.S. coke production is expected to be nearly 1.1 million
tons in fourth quarter 2012, up an estimated 67 thousand tons
versus fourth quarter 2011. Full year 2012 U.S. coke production
is expected to be more than 4.3 million tons, up an estimated 580
thousand tons versus 2011.
Senior Vice President and CFO Mark Newman bought 4,200 shares of
SXCP stock on 01/18/2013 at the average price of 19. Mark Newman
owns at least 4,200 shares after this.
Progenics Pharmaceuticals, Inc. (
PGNX
): CEO Mark Robert Baker Bought 1,215 Shares
CEO of Progenics Pharmaceuticals, Inc. (
PGNX
) Mark Robert Baker bought 1,215 shares on 01/22/2013 at an
average price of $2.91. Progenics Pharmaceuticals Inc. or
Progenics, is a biopharmaceutical company focusing on the
development and commercialization of innovative therapeutic
products to treat the unmet medical needs of patients with
debilitating conditions and life-threatening diseases. Progenics
Pharmaceuticals, Inc. has a market cap of $98 million; its shares
were traded at around $2.91 with and P/S ratio of 13.2.
PGNX recently reported its third quarter 2012 financial results.
Net loss for the third quarter of 2012 was $11.3 million or $0.33
basic and diluted per share, compared to net loss of $11.4
million or $0.34 per share in the 2011 period. Net loss for the
nine months ended Sept. 30, 2012 was$35.1 million or $1.04 basic
and diluted per share, compared to net income of $21.1 million or
$0.63 per share in 2011.
For the complete list of stocks that bought by their company
CEOs, go to:
http://www.gurufocus.com/InsiderBuy.php?position=ceoAbout
GuruFocus: GuruFocus.com tracks the stocks picks and portfolio
holdings of the world's best investors. This value investing site
offers stock screeners and valuation tools. And publishes daily
articles tracking the latest moves of the world's best investors.
GuruFocus also provides promising stock ideas in 3 monthly
newsletters sent to
Premium Members
.